What the FDA labels say about taking them together
Aliskiren and valsartan
Valsartan's FDA label of August 5, 2026 names aliskiren in its contraindications section; aliskiren's label does not name valsartan itself but warns about its class (ARBs (angiotensin II receptor blockers)). The valsartan label: “Do not coadminister aliskiren with Diovan in patients with diabetes.”
Check it at the source: the aliskiren FDA label on DailyMed (effective March 7, 2024, LXO US Inc.); the valsartan FDA label on DailyMed (effective August 5, 2026, Macleods Pharmaceuticals Limited).
What does the aliskiren label say about valsartan?
Aliskiren's label does not name valsartan itself; it warns about its class (ARBs (angiotensin II receptor blockers)):
Aliskiren label, warnings and precautionsRenal Impairment/Hyperkalemia/Hypotension when Tekturna is Given in Combination with ARBs or ACEIs Tekturna is contraindicated in patients with diabetes who are receiving ARBs or ACEIs because of the increased risk of renal impairment, hyperkalemia, and hypotension.
Aliskiren label, contraindicationsCONTRAINDICATIONS Do not use Tekturna with ARBs or ACEIs in patients with diabetes [see Warnings and Precautions ( 5.2 ) and Clinical Studies ( 14.3 )].
Source: FDA drug label (Tekturna), NDA021985 (Lxo Ireland), as published by LXO US Inc., effective March 7, 2024 (SPL set 3dd61fa5-1620-4ebf-bbdb-ede29b92fce2), via openFDA; the full label on DailyMed
What does the valsartan label say about aliskiren?
Valsartan label, contraindicationsDo not coadminister aliskiren with valsartan in patients with diabetes [see Drug Interactions ( 7.3 )].
Valsartan label, drug interactionsBlockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy.
Source: FDA drug label (Diovan, NDA021283), Novartis Pharmaceuticals Corporation, effective August 11, 2026 (SPL set 5ddba454-f3e6-43c2-a7a6-58365d297213), via openFDA
Source: FDA drug label (Valsartan), Macleods Pharmaceuticals Limited, effective August 5, 2026 (SPL set 251ccff4-bf86-453b-9d1c-e3c1ecfd3a46), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Aliskiren | Valsartan | |
|---|---|---|
| Labeled for | High blood pressure | High blood pressure, Heart failure |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $3.94 per tablet 150 mg tablet | $0.0963 per tablet 40 mg tablet |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once